Patent ID: 6090916
Filing Date: 2000-07-18
Classification: A61K,A61P,C07K,C12P,Y10S

Abstract:
An isolated protein having anticoagulant activity, including factor Xa inhibitory activity, and having one or more NAP domains, where each NAP domain includes the sequence:Cys-A1-Cys-A2-Cys-A3-Cys-A4-Cys-A5-Cys-A6-Cys-A7-Cys-A8-Cys-A9-Cys-A10 (Formula II), wherein(a) A1 is an amino acid sequence of 7 to 8 amino acid residues;(b) A2 is an amino acid sequence;(c) A3 is an amino acid sequence of 3 amino acid residues;(d) A4 is an amino acid sequence;(e) A5 is an amino acid sequence of 3 to 4 amino acid residues;(f) A6 is an amino acid sequence;(g) A7 is an amino acid residue;(h) A8 is an amino acid sequence of 11 to 12 amino acid residues;(i) A9 is an amino acid sequence of 5 to 7 amino acid residues; and(j) A10 is an amino acid sequence;wherein each A2, A4, A6 and A10 has an independently selected number of independently selected amino acid residues and each sequence is selected such that each NAP domain has in total less than about 120 amino acid residues and wherein said NAP domain includes the amino acid sequence:Cys-A1-Cys-A2-Cys-A3-Cys-A4-Cys-A5-Cys-A6-Cys-A7-Cys-A8-Cys-A9-Cys-A10wherein(a) Cys-A1 is selected from SEQ.ID.NOS. 67 and 156;(b) Cys-A2-Cys is selected from one of SEQ.ID.NOS. 157 to 159;(c) A3-Cys-A4 is selected from one of SEQ.ID.NOS. 160 to 173;(d) Cys-A5 is selected from SEQ.ID.NOS. 174 and 175;(e) Cys-A6 is selected from one of SEQ.ID.NOS. 176 to 178;(f) Cys-A7-Cys-A8 is selected from SEQ.ID.NOS. 179 and 180;(g) Cys-A9 is selected from one of SEQ.ID.NOS. 181 to 183; and(h) Cys-A10 is selected from one of SEQ.ID.NOS. 184 to 204.